Provided is use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia. Specifically, provided is a nitrogen-containing bisphosphonate in combination with a glucocorticoid for use in treating or ameliorating coronavirus infections, the nitrogen-containing bisphosphonate is selected from the group consisting of pamidronate, alendronate, risedronate, ibandronate, zoledronate, minodronate and incadronate. The glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone, fluticasone propionate, beclomethasone dipropionate, budesonide and mometasone furoate.

Provided is use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia. Specifically, provided is a nitrogen-containing bisphosphonate in combination with a glucocorticoid for use in treating or ameliorating coronavirus infections, the nitrogen-containing bisphosphonate is selected from the group consisting of pamidronate, alendronate, risedronate, ibandronate, zoledronate, minodronate and incadronate. The glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone, fluticasone propionate, beclomethasone dipropionate, budesonide and mometasone furoate.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine, or a pharmaceutically acceptable salt or solvate thereof, b) benzalkonium chloride, in combination with at least one further preservative selected from the group comprising phenylethyl alcohol, benzyl alcohol, sodium benzoate, chlorbutanol, phenoxyethanol, cetrimide and 2-(ethylmercuriomercapto)benzoic acid sodium salt, c) a suspending agent, and d) 2-hydroxypropyl-β-cyclodextrin;
wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5.

The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H.sub.1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.

The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine, or a pharmaceutically acceptable salt or solvate thereof, b) benzalkonium chloride, in combination with at least one further preservative selected from the group comprising phenylethyl alcohol, benzyl alcohol, sodium benzoate, chlorbutanol, phenoxyethanol, cetrimide and 2-(ethylmercuriomercapto)benzoic acid sodium salt, c) a suspending agent, and d) 2-hydroxypropyl-β-cyclodextrin;
wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5.

The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H.sub.1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.

The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

Provided is a method of treatment of COVID-19 and/or preventing infection with SARS-CoV-2 comprising: administering to an individual in need thereof a therapeutically effective dose of mifepristone, or a pharmaceutically acceptable salt and/or analogue thereof, and a therapeutically effective dose of amlodipine, or a pharmaceutically acceptable salt thereof.

Provided is a method of treatment of COVID-19 and/or preventing infection with SARS-CoV-2 comprising: administering to an individual in need thereof a therapeutically effective dose of mifepristone, or a pharmaceutically acceptable salt and/or analogue thereof, and a therapeutically effective dose of amlodipine, or a pharmaceutically acceptable salt thereof.